Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release

Opiant Pharmaceuticals (NASDAQ: OPNT) has announced that a press release issued on April 29, 2022, claiming a partnership with Hikma Pharmaceuticals is false.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Opiant Pharmaceuticals (NASDAQ: OPNT) has announced that a press release issued on April 29, 2022, claiming a partnership with Hikma Pharmaceuticals is false. Opiant confirmed it had no involvement or knowledge of the release distributed by Cision PR Newswire, which incorrectly stated a $225 million commercialization agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. Cision has issued a notice advising the public to disregard the false news. Opiant directs all inquiries regarding this matter to Cision.

Positive

None.

Negative

False information can harm investor trust and stock performance.
No partnership with Hikma Pharmaceuticals may limit growth opportunities.

Argus Session date unavailable

+8.42% session move Open Argus

Details

News Market Reaction – OPNT

The recorded move for OPNT in the trading session of this news was +8.42%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/29/2022 - 12:47 PM EDT

SANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC.

Opiant had no knowledge of the press release issued by Cision PR Newswire, and it is fake. Opiant and Hikma are not involved in any discussions of this type.

Cision PR Newswire issued a notice across its service confirming that journalists, investors and other readers should disregard the news release, "Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK" issued April 29, 2022, over Cision PR Newswire.

All further questions should be directed to Cision PR Newswire.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com

View original content:https://www.prnewswire.com/news-releases/opiant-pharmaceuticals-issues-statement-in-response-to-fake-press-release-301536458.html

SOURCE Opiant Pharmaceuticals, Inc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the fake news release about Opiant Pharmaceuticals?

The fake news release falsely claimed Opiant announced a $225 million partnership with Hikma Pharmaceuticals for OPNT003.

When was the false press release about Opiant issued?

The false press release was issued on April 29, 2022.

What should investors do regarding the fake press release?

Investors should disregard the fake press release and refer to Cision PR Newswire for confirmation.

How did Opiant respond to the fake news?

Opiant confirmed the news was false and stated they had no knowledge of the release.

Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release